IFEC 20925
INSTITUTO DE FARMACOLOGIA EXPERIMENTAL DE CORDOBA
Unidad Ejecutora - UE
artículos
Título:
Assessment of Potential Thrombogenicity in an Animal Model of a Triple Viral Inactivated Factor IX Concentrate Manufactured in Argentina
Autor/es:
R, RODRIGUEZ; HA, GUGLIELMONE; GR, CUADRA; A, MARINSALDI; ME, BERNARDI; MC, MARTINEZ; GR, RODRIGUEZ; A, VALDOMERO
Revista:
Annals of Hematology & Oncology
Editorial:
Austin Publishing Group
Referencias:
Lugar: Irving-Texas; Año: 2021 vol. 8 p. 1343 - 1345
ISSN:
2375-7965
Resumen:
The risk of thromboembolism with FIX replacement therapy remainsa concern for hemophilic B patients. Previous studies from our laboratorydemonstrated that the activated factor content of the FIX Plasma Derived(FIXpd) manufactured at UNC-Hemoderivados was negligible by in vitro assay.Despite this, we considered it important to conduct studies to assess thepotential thrombogenic risk of our FIXpd concentrates using a modified stasisanimal model.FIXpd were inject doses of 100 or 200 IU F IX kg-1 and some samples weresupplemented with heparin (
